Habiger's $100,000 purchase expanded his direct holdings by 14%, signaling confidence despite the stock's recent weakness. The acquisition came as shares traded near their lowest levels in over a year ...

Mahoney expanded his equity stake by 13% following a -54% one-year stock decline. His combined holdings now total ~1.6 million shares valued at $78.08 million.

A clash of financial forces, both good and bad, largely offset one another Wednesday as executives at medical device maker Boston Scientific sought to emphasize a positive new product approval and ...

Boston Scientific faces device recall concerns as innovation, margin expansion, regulatory execution, and its broader ...

The trial launch comes as Boston Scientific faces competitive pressures for pulsed-field ablation (PFA) market share.

The company's cardiovascular business faces new rivals in pulsed field ablation and heart devices. A restructuring plan aims to cut $500 million in annual expenses.

Boston Scientific (NYSE: BSX) has initiated multiple product recalls covering cardiac ablation generators and vascular access ...

By Siddhi Mahatole July 29 (Reuters) - Medical device maker Boston Scientific cut its annual profit forecast on Wednesday, ...

Confusion over when and if to use the Watchman implant to reduce stroke risks in patients with irregular heartbeats is hurting Boston Scientific — and could put the Twin Cities in the crosshairs of ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. WASHINGTON (AP) — U.S. health regulators are ...

Despite U.S. growth headwinds for WATCHMAN and electrophysiology, Boston Scientific delivered strong Q2 2026 results. Read why BSX stock is a Strong Buy.